AnaMorelin hydrochloride Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
Anamorelin Monohydrochloride, also known as ONO-7643, RC-1291, and ST-1291, is a drug developed by Novo Nordisk A/S and later licensed by Helsinn Healthcare SA and Ono Pharmaceutical Co. Anamorelin is used for the treatment of cancer anorexia and cachexia syndrome (CACS), a cancer-related side effect manifested by loss of appetite, weight loss, muscle wasting, and reduced quality of life.
AnaMorelin hydrochloride Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte